Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction

Annals of Internal Medicine

Volumn 126, Issue 4, 1997, Pages 296-306

  Aronson, Doron ^a   Rayfield, Elliot J ^b   Chesebro, James H ^b  

^a JOSLIN DIABETES CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; SIMVASTATIN; STREPTOKINASE; UROKINASE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0031051579     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-4-199702150-00006     Document Type: Review

References (173)

1. Consensus statement: role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. American Diabetes Association. Diabetes Care. 1993;16(Suppl 2):72-8.
2. Morrish NJ, Stevens LK, Head J, Fuller JH. Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia. 1990;33:538-41.
3. Jaffe AS. Spadaro 11, Schechtman K, Roberts R, Geltman EM, Sobel BE. Increased congestive heart failure after myocardial infarction of modest extent in diabetic patients mellitus. Am Heart J. 1984; 108:31-7.
4. Stone PH, Muller JE. Hartwell T, York BJ. Rutherford JD, Parker CB, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. 1989:14:49-57.
5. Smith JW, Marcus Fl, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 1984;54:718-21.
6. Herlitz J, Malmberg K, Karlson BW, Rydén L, Hjalmarson A. Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand. 1988:244:31-8.
7. Savage MP, Krolewski AS, Kenien GG, Lebeis MP, Christlieb AR, Lewis SM. Acute myocardial infarction in diabetes mellitus and significance of congestive heart failure as a prognostic factor. Am J Cardiol. 1988,62(10 Pt 1):665-9.
8. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in diabetic patients. Diabetes Care. 1985:8:230-4.
9. Czyzk A. Krolewski AS, Szablowska S, Alot A, Kopczynski J. Clinical course of myocardial infarction among diabetic patients. Diabetes Care. 1980:3:526-9.
10. Tansey MJ, Opie LH, Kennelly BM. High mortality in obese women diabetics with acute myocardial infarction. Br Med J. 1977;1:1624-6.
11. Kouvaras G, Cokkinos D, Spyropoulou M. Increased mortality of diabetics after acute myocardial infarction attributed to diffusely impaired left ventricular performance as assessed by echocardiography. Jpn Heart J. 1988;29: 1-9.
12. Malmberg K, Rydén L Myocardial infarction in patients with diabetes mellitus. Eur Heart J. 1988:9:259-64.
13. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol. 1993:21:920-5.
14. Lomuscio A, Castagnone M, Vergani D, Verzoni A, Beltrami A, Ravaglia R, et al. Clinical correlation between diabetic and non diabetic patients with myocardial infarction. Acta Cardiol. 1991:46:543-54.
15. Yudkin JS, Oswald GA. Determinants of hospital 'admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care. 1983; 11:351-8.
16. Abbud ZA, Shindler DM, Wilson AC, Kostis JB. Effect of diabetes mellitus on short- and long-term mortality rates of patients with acute myccardial infarction: a statewide study. Myocardial Infarction Data Acquisition System Study Group. Am Heart J. 1995:130:51-8.
17. Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet. 1984:1:1264-7.
18. Lehto S, Pyörälä K, Miettinen H, Ronnemaa T, Palomaki P, Tuomilehto J, et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med. 1994:236:291-7.
19. Orlander PR, Goff DC, Morrissey M, Ramsey DJ, Wear ML, Labarthe DR, et al. The relation of diabetes to the severity of acute myccardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. Diabetes. 1994;43:897-902.
20. Ulvenstam G, Aberg A, Bergstrand R, Johansson S, Pennert K, Vedin A, et al. Long term prognosis after myocardial infarction in men with diabetes. Diabetes. 1985:34:787-92.
21. Gwilt DJ. Pétri M, Lewis PW. Nattrass M, Pentecost BL Myocardial infarct size and mortality in diabetic patients. Br Heart J. 1985;54:466-72.
22. Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med. 1993; 10:449-54.
23. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983;309:331-6.
24. Lee KL, Woodlief LH, Topol EJ, Weaver WD. Betriu A, Col J, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-1 Investigators. Circulation. 1995;91:1659-68.
25. Fava S. Azzopardi J, Muscat HA, Fenech FF. Factors that influence outcome in diabetic subjects with myocardial infarction. Diabetes Care. 1993:16:1615-8.
26. Zuanetti G, Latin! R, Maggioni AP, Santoro L, Franzosi MG. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol. 1993;22:1788-94.
27. Iwasaka T, Takahashi N, Nakamura S, Sugiura T, Tarumi N, Kimura Y, et al. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care. 1992; 15:1522-6.
28. Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J. 1989; 118(5 Pt 1): 1000-12.
29. Grines CL, Topol EJ, Califf RM, Stack RS, George BS, Kereiakes D. et al. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups. Circulation. 1989;80:245-53.
30. Jaarsma W, Visser ÇA, Eenige van MJ, Res JC, Funke Kupper AJ, Verbeugt FW, et al. Prognostic implications of regional hyperkinesia and remote asynergy of noninfarcted myocardium. Am J Cardiol. 1986;58:394-8.
31. Takahashi N, Iwasaka T, Sugiura T, Hasegawa T, Tarumi N, Kimura Y, et al. Left ventricular regional function after acute anterior myocardial infarction in diabetic patients. Diabetes Care. 1989;12:630-5.
32. Zarich SW. Arbuckle BE, Cohen LR. Roberts M, Nesto RW. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol. 1988; 12:114-20.
33. Uusitupa M, Mustonen J, Laakso M, Vainio P, Lansimies E, Talwar S, et al. Impairment of diastolic function in middle-aged type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients free of cardiovascular disease. Diabetologia. 1988;31:783-91.
34. Riggs TW, Transue D. Doppler echocardiographic evaluation of left ventricular diastolic dysfunction in adolescents with diabetes mellitus. Am J Cardiol. 1990;65:899-902.
35. Raev DC Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care. 1994;17:633-9.
36. Paillole C, Dahan M, Paycha F, Solal AC Passa P, Gourgon P. Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. Am J Cardiol. 1989;64:1010-6.
37. Mildenberger RR, Bar-Shlomo B, Druck MN, Jablonsky G, Morch JE, Hilton JD, et al. Clinically unrecognized ventricular dysfunction in young diabetic patients. J Am Coll Cardiol. 1984;4:234-8.
38. Shapiro LM, Leatherdale BA, Mackinnon J, Fletcher RF. Left ventricular function in diabetes mellitus. II: Relation between clinical features and left ventricular function. Br Heart J. 1981;45:129-32.
39. Epstein M, Sowers Diabetes mellitus and hypertension. Hypertension. 1992;19:403-18.
40. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996; 125:304-10.
41. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990;82:848-55.
42. Vered A. Battler A, Segal P, Uberman D, Yerushalmi Y, Berezin M, et al. Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). Am J Cardiol. 1984;54: 633-7.
43. Mustonen JN, Uusitupa Ml, Laakso M, Vanninen E, Lansimies E, Kuikka JT, et al. Left ventricular systolic function in middle-aged diabetic patients mellitus. Am J Cardiol. 1994;73:1202-8.
44. Clements IP. Brown ML, Zinsmeister AR, Gibbons RJ. Influence of left ventricular diastolic filling on symptoms and survival in patients with decreased left ventricular systolic function. Am J Cardiol. 1991;67:1245-50.
45. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographie Investigators. N Engl J Med. 1993;329: 1615-22.
46. Muller DW, Topol EJ, Ellis SG, Sigmon KN, Lee K, Califf RM. Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J. 1991; 121(4 Pt 1):1042-9.
47. Barzilay Jl, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged 65 years (report from the coronary artery surgery study [CASSI registry). Am J Cardiol. 1994,74:334-9.
48. Waller BF, Palumbo PJ. Lie JT. Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without evidence of coronary heart disease and comparison to 183 control subjects. Am J Med. 1980;69: 498-506.
49. Mueller HS, Cohen LS. Braunwald E, Forman S. Feit F, Ross A, et al. Predictors of early mortality and morbidity after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II. Circulation. 1992:85:1254-64.
50. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995:91:979-89.
51. Vigorito C, Betocchi S, Bonzani G, Giudice P. Miceli D, Piscione F. et al. Severity of coronary artery disease in diabetic patients mellitus. Angiographie study of 34 diabetic and 120 nondiabetic patients. Am Heart J. 1980:100(6 Pt 1):782-7.
52. Ginsberg NH. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care. 1991;14:839-55.
53. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990:10:493-6.
54. Umans JG, Levi R. Nitric oxide in the regulation of blood flow and arterial pressure. Annu Rev Physio!. 1995:57:771-90.
55. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993:88:2510-6.
56. Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation. 1993;87(Suppl 5):67-76.
57. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radie Biol Med. 1994;16:383-91.
58. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with aniographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993:42:1017-25.
59. Pieper GM, Jordan M, Adams MB, Roza AM. Syngeneic pancreatic islet transplantation reverses endothelial dysfunction in experimental diabetes. Diabetes. 1995:44:1106-13.
60. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol. 1992:263(2 Pt 2):H321-6.
61. Keegan A, Walbank H, Cotter MA, Cameron NE. Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Diabetologia. 1995:38:1475-8.
62. Bucala R, Tracey KJ. Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest. 1991:87:432-8.
63. Kersten JR, Brooks LA, Dellsperger KC. Impaired microvascular response to graded coronary occlusion in diabetic and hyperglycémie dogs. Am J Physiol. 1995:268(4 Pt 2):H1667-74.
64. Sebbag L, Forrat R, Canet E, Wiernsperger N, Delaye J, Renaud S, et al. Effect of experimental non-insulin requiring diabetes on myocardial microcirculation during ischemia in dogs. Eur J Clin Invest. 1994:24:686-90.
65. Nastier PJ Jr, Brown RE. Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation. 1995:91:635-40.
66. Griffith TM, Edwards DH, Davies RL, Harrison TJ, Evans KT. EDRF coordinates the behavior of vascular resistance vessels. Nature. 1987;329: 442-5.
67. Liu Y, Thornton JD, Cohen MV, Downey JM, Schaffer SW. Streptozotocin-induced non-insulin-dependent diabetes protects the. heart from infarction. Circulation. 1993:88:1273-8.
68. Tani M, Neely Hearts from diabetic rats are more resistant to in vitro ischemia: possible role of altered Ca2metabolism. Circ Res. 1988:62:931-40.
69. Braunwald E. Acute myocardial infarction-the value of being prepared [Editorial). N Engl J Med. 1996:334:51-2.
70. Zaninetti D. Greco-Perotto R, Jaenrenaud B. Heart glucose transport and transporters in rat heart: regulation by insulin, workload and glucose. Diabetologia. 1988:31:108-13.
71. Wheeler TJ. Translocation of glucose transporters in response to anoxia in heart. J Biol Chem. 1988;263:19447-54.
72. Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius FC 3d. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 of the plasma membrane of cardiac monocytes. Circulation. 1994:89:793-8.
73. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischémie heart. Prog Cardiovasc Dis. 1981:23:321-36.
74. Eberli FR, Weinberg EO, Grice WN, Horowitz GL, Apstein CS. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion and reperfusion in isolated rabbit hearts perfused with erythrocyte suspensions. Circ Res. 1991:68:466-81.
75. Runnman EM, Lamp ST, Weiss JN. Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux. J Clin Invest. 1990:86:1222-33.
76. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol. 1995:27:169-79.
77. vom Dahl J, Herman WH, Hicks RJ, Ortiz-Alonso FJ. Lee KS, Allman KC, et al. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed quantitatively by dynamic positron emission tomography. Circulation. 1993:88:395-404.
78. Ohtake T, Yokoyama I, Watanabe T, Momose T, Serezawa T, Nishikawa J, et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med. 1995:36:456-63.
79. Clark RS. English M. McNeill GP. Newton RW. Effea of intravenous infusion of insulin in diabetics with acute myocardial infarction. Br Med J (Clin Res Ed). 1985:291:303-5.
80. Gwilt DJ, Petri M, Lamb P, Nattrass M, Pentecost BL. Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction. Br Heart J. 1984:51:626-30.
81. Malmberg K, Rydén U Efendic S, Herlitz J, Nicol P. Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26: 57-65.
82. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988:2:349-60.
83. Lynch M. Gammage MD, Lamb P, Nattrass M, Pentecost BL Acute myocardial infarction in diabetic patients in the thrombolytic era. Diabet Med. 1994:11:162-5.
84. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more then 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343:311-22.
85. Barbash Gl, White HD, Modan M, Van de Werf F. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol. 1993:22:707-13.
86. Hillis LD, Forman S, Braunwald E. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators. J Am Coll Cardiol. 1990:16:313-5.
87. Murphy JF, Kahn MG, Krone RJ. Prethrombolytic versus thrombolytic era risk stratification of patients with acute myocardial infarction. Am J Cardiol. 1995:76:827-9.
88. Klein HH, Hengstenberg C, Peuckert M, Jürgensen R. Comparison of death rates from acute myocardial infarction in a single hospital in two different periods (1977-1978 versus 1988-1989). Am J Cardiol. 1993:71: 518-23.
89. Harrison JK, Califf RM, Woodlief LH, Kereiakes D, George BS, Stack RS, et al. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group. Circulation. 1993:87:1531-41.
90. Braunwald E. The open-artery theory is alive and well - again [Editorial]. NEnglJMed. 1993:329:1650-2.
91. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, et al. Link between the angiographie substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-1 Investigators. Circulation. 1995:91:1923-8.
92. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. NEnglJMed. 1993;329:703-9.
93. Reiner JS, Lundergan CF, van den Brand M, Boland J, Thompson MA, Machecourt J, et al. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographie study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol. 1994;24:1439-44.
94. Lincoff MA, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 1993:88:1361-74.
95. Ohman EM. Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. The TAMI Study Group. Circulation. 1990:82: 781-91.
96. Gray RP, Yudkin JS, Patterson DL Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor? Br Heart J. 1993;70: 530-6.
97. Ouriel K, Shortell CK, Azodo MV, Guiterrez OH, Marder VJ. Acute peripheral arterial occlusion: predictors of success in catheter-directed thrombolytic therapy. Radiology. 1994:193:561-6.
98. Anderson JL. Karagounis LA. Becker LC, Sorensen SG, Menlove RL TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation. 1993:87: 1829-39.
99. Coller BS. Platelet and thrombolytic therapy. N Engl J Med. 1990:322:33-42.
100. Chesebro JH, Fuster V. Dynamic thrombosis and thrombolysis. Role of antithrombins [Editorial]. Circulation. 1991:83:1815-7.
101. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes. 1992; 41(Suppl 2):26-31.
102. Tschöepe D, Röesen P, Schwippert B, Cries FA. Platelets in diabetes: the role of the hemostatic regulation in atherosclerosis. Semin Thromb Hemost. 1993:19:122-8.
103. Tschöepe D. Driesch E. Schwippert B, Nieuwenhuis HK, Cries FA. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes. 1995; 44:890-4.
104. Tschöepe D, Röesen P, Esser J, Schwippert B, Nieuwenhuis HK, Kehrel B, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost. 1991:17:433-8.
105. Davi G, Catalane I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, et al. Thromboxane biosynthesis and platelets function in type II diabetes mellitus. N Engl J Med. 1990:322:1769-74.
106. Sane DC. Stump DC. Topol EJ, Sigmon KN, Kereiakes DJ, George BS, et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with issue plasminogen activator for acute myocardial infarction. Thromb Haemost. 1991:65:275-9.
107. Barbash G1. Hod H, Roth A, Miller HI. Rath S. Zahav YH. et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 1989,64:1231-5.
108. McGill JB. Schneider DJ, Arfken CL, Lucore CU Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994:43:104-9.
109. Juhan-Vague I, Alessi MC. Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991:34:457-62.
110. Nordt TK, Sawa H, Fujïi S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995; 91:764-70.
111. Keyt BA. Nicholas PF, Refino CJ. Berleau L. Nguyen H. Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994:91:3670-4.
112. Gilpin E, Ricou F, Dittrich H, Nicod P, Henning H, Ross J Factors associated with recurrent myocardial infarction within one year after acute myocardial infarction. Am Heart J. 1991:121(2 Pt 1):457-65.
113. Herlitz J, Karlson BW, Edvardsson N, Emanuelsson H, Hjalmarson A. Prognosis in diabetics with chest pain or other symptoms suggestive of acute myocardial infarction. Cardiology. 1992:80:237-45.
114. Abbott RD. Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham study. JAMA. 1988:260:3456-60.
115. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20: 736-44.
116. Milo C, Reicher-Reiss H. Goldbourt U, Boyko V, Behar S. Comparison of prognosis of acute myocardial infarction in insulin-treated diabetic women versus men. The SPRINT Study Group. Am J Cardiol. 1994;74: 1275-6.
117. Capone RJ, Pawitan Y, el-Sherif N, Geraci TS, Handshaw K. Morganroth J, et al. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. J Am Coll Cardiol. 1991; 18:1434-8.
118. Taylor GJ, Moses HW, Katholi RE. Korsmeyer C. Kolm P. Dove JT, et al. Six-year survival after coronary thrombolysis and early revascularization for acute myocardial infarction. Am J Cardiol. 1992;70:26-30.
119. Woo KS, White HD. Factors affecting outcome after recovery from myocardial infarction. Annu Rev Med. 1994;45:325-39.
120. Pitt B. Evaluation of the postinfarct patient. Circulation. 1995:91:1855-60.
121. Iwasaka T, Sugiura T, Abe Y, Karakawa M, Matsui Y, Wakayama Y, et al. Residual left ventricular pump function following acute myocardial infarction in postmenopausal diabetic women. Coron Artery Dis. 1994;5: 237-42.
122. Schulman SP. Achuff SC. Griffith LS, Humphries JO, Taylor GJ, Mellits ED, et al. Prognostic cardiac catheterization variables in survivors of acute myocardial infarction: a five year prospective study. J Am Coll Cardiol. 1988; 11:1164-72.
123. Fuster V, Badimon U Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992:326:242-50, 310-8.
124. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91;2844-50.
125. Suva JA, Escobar A, Collins TJ, Ramee SR, White CJ. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation. 1995;92:1731-6.
126. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995:332:635-41.
127. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperactivity and prognosis in survivors of myocardial infarction. N Engl J Med. 1990:322: 1549-54.
128. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J. 1991:66:351-5.
129. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987:2:3-9.
130. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986:2:533-7.
131. Cooper J. Douglas AS. Fibrinogen level as a predictor of mortality in survivors of myocardial infarction. Fibrinolysis. 1991;5:105-8.
132. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992:340:319-23.
133. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Thromb Haemost. 1993;70:380-5.
134. Kannel WB, D'Agostino RE, Wilson PW, Belanger AJ, Cagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990; 120:672-6.
135. De Feo P, Gaisano GM, Raymond MW. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest. 1991;88:833-40.
136. Ganda OP, Arkin CF. Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care. 1992;15:1245-50.
137. Ceriello A, Giugliano D. Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia. 1988:31:889-91.
138. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes. 1994;43:426-9.
139. Esposito C, Gerlach H. Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface procoagulant properties. J Exp Med. 1989; 170:1387-407.
140. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arteriosder Thromb. 1993; 13:1822-8.
141. Johnson M, Harrison HE, Raftery AT, Elder JB. Vascular, prostacyclin may be reduced in diabetes in man [Letter]. Lancet. 1979;1:325-6.
142. Umeda F, Inoguchi T, Nawata H. Reduced stimulatory activity on prostacyclin production by cultured endothelium cells in serum from aged diabetic patients. Atherosclerosis. 1989;75:61-6.
143. Van Ravenswaaij-Arts CM, Kollée LA, Hopman JC, Stoelinga GB, van Geijn HP. Heart rate variability. Ann Intern Med. 1993; 118:436-47.
144. Kleiger RE, Miller IP, Bigger JT Jr, Moss AI. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 1987;59:256-62.
145. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation. 1995:91:2591-5.
146. O'Brien IA, McFadden IP, Corrall RJ. The influence of autonomie neuropathy on mortality in insulin-dependent diabetes. Q J Med. 1991:79:495-502.
147. Sampson MJ, Wilson S, Karagiannis P, Edmonds M, Watkins PJ. Progression of diabetic autonomie neuropathy over a decade in insulin dependent diabetics. Q J Med. 1990:75:635-46.
148. Ewing DJ, Campbell IW, Clarke BF. Mortality in diabetic autonomie neuropathy. Lancet. 1976;1:601-3.
149. Rollins MD, Jenkins JG, Carson DJ. McClure BG. MiUhell RH, Iman SZ. Power spectral analysis of the electrocardiogram in diabetic children. Diabetologia. 1992:35:452-5.
150. Pfeifer MA, Weinberg CR, Cook DU Reenan A, Halter JB, Ensinck JW, et al. Autonomie neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care. 1984:7:447-53.
151. Malpas SC, Mating TJ. Heart-rate variability and cardiac autonomie function in diabetes. Diabetes. 1990:39:1177-81.
152. Bernard! L, Ricordi L, Lazzari P, Solda P, Calciati A, Ferrari MR, et al. Impaired circadian modulation of sympatovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation. 1992:86:1443-52.
153. Zarich S, Waxman S, Freeman RT, Mittleman M, Hegarty P, Nesto RW. Effect of the autonomie nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol. 1994; 24:956-62.
154. Kendall MJ, Lynch KP, Hjalmarson A, Kjekshus J. β-blockers and sudden cardiac death. Ann Intern Med. 1995;123;358-67.
155. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty In Myocardial Infarction Study Group. N Engl J Med. 1993;328:673-9.
156. Zijlstra F. de Boer MJ, Hoorntje 1C. Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993;328: 680-4.
157. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ. Immediate angioplasty compared with administration of a thrombolytic agent following by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med. 1993;328:685-91.
158. Ribeiro EE, Silva LA, Carneiro R, D'Oliveira LG, Gasquez A, Amino JG, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol. 1993;22: 376-80.
159. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med. 1996;335:1253-60.
160. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996;27:528-35.
161. Moliterno DJ. Califf RM, Andersen K. Weisman HF, Topol EJ. Special considerations in diabetics receiving platelet llb/llla antagonists during coronary interventions. Results from the EPIC Trial [Abstract]. J Am Coll Cardiol. 1995;25:155A.
162. Comparison of bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med. 1996;335:217-25.
163. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
164. DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood. 1986;68:886-91.
165. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care. 1983;6:285-90.
166. Malmberg K, Herlitz J, Hjalmarson A, Rydén L Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies. Eur Heart J. 1989; 10: 423-8.
167. Kjekshus J, Gilpin E, Call G, Blackey AR, Henning H, Ross J Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J. 1990;11:43-50.
168. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med. 1994;11:137-44.
169. Zuanetti G, Latin! R, Maggioni AP, Santoro L, Franzosi M, Tognoni G. Prognosis of diabetic patients after myocardial infarction: effect of early treatment with ACE-inhibitors. The GISSI-3 Investigators [Abstract]. J Am Coll Cardiol. 1996;27:319A.
170. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (45). Lancet. 1994;344:1383-9.
171. Bloomgarden ZT. Cardiovascular disease and diabetes: issues raised at the European Association for the Study of Diabetes annual meeting. Diabetes Care. 1996; 19:187-90.
172. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995;332: 512-21.
173. Ting HH, Timimi FK. Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996;97:22-8.